{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:54:20Z","timestamp":1791273260588,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.ijrobp.2009.05.008","type":"journal-article","created":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T07:02:36Z","timestamp":1265007756000},"page":"409-413","source":"Crossref","is-referenced-by-count":3,"title":["Phase I Study of Daily Irinotecan as a Radiation Sensitizer for Locally Advanced Pancreatic Cancer"],"prefix":"10.1016","volume":"77","author":[{"given":"Christelle","family":"de la Fouchardi\u00e8re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"N\u00e9grier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"Labrosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Martel Lafay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Desseigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"M\u00e9eus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Petit-Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Rivoire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Carrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2009.05.008_bib1","series-title":"Cancer: Principles and practice of oncology","first-page":"1054","article-title":"Cancer of the pancreas","author":"Yeo","year":"2005"},{"key":"10.1016\/j.ijrobp.2009.05.008_bib2","first-page":"1558","article-title":"Inoperable pancreatic cancer: Standard of care","volume":"21","author":"Wisinski","year":"2007","journal-title":"Oncology"},{"key":"10.1016\/j.ijrobp.2009.05.008_bib3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.semradonc.2005.04.003","article-title":"Radiochemotherapy in the management of pancreatic cancer\u2014Part II: Use in adjuvant and locally unresectable settings","volume":"15","author":"Dickler","year":"2005","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2009.05.008_bib4","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4","article-title":"Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group","volume":"48","author":"Moertel","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2009.05.008_bib5","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0360-3016(02)02980-2","article-title":"Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer","volume":"54","author":"Poggi","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.05.008_bib6","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","volume":"19","author":"Chauffert","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2009.05.008_bib7","first-page":"605","article-title":"Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I","volume":"49","author":"Boothman","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2009.05.008_bib8","first-page":"5813","article-title":"Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864)","volume":"51","author":"Mattern","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2009.05.008_bib9","first-page":"266","article-title":"Daily low dose irinotecan (CPT11) plus pelvis irradiation as preoperative treatment of locally advanced rectal cancer","volume":"18","author":"Minsky","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ijrobp.2009.05.008_bib10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s002800100360","article-title":"A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma","volume":"48","author":"Konstadoulakis","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ijrobp.2009.05.008_bib11","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/annonc\/mdl427","article-title":"FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: Results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study","volume":"18","author":"Taieb","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2009.05.008_bib12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00002018-200124050-00002","article-title":"Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer","volume":"24","author":"Jansman","year":"2001","journal-title":"Drug Saf"},{"key":"10.1016\/j.ijrobp.2009.05.008_bib13","series-title":"ICRU Report 62","year":"1999"},{"key":"10.1016\/j.ijrobp.2009.05.008_bib14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2009.05.008_bib15","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/sj.bjc.6604292","article-title":"Irinotecan+5-fluorouracil with concomitant pre-operative radiotherapy in locally advanced non-resectable rectal cancer: A phase I\/II study","volume":"98","author":"Iles","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2009.05.008_bib16","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1159\/000061220","article-title":"Topotecan as a 21-day continuous infusion with accelerated 3D-conformal radiation therapy for patients with glioblastoma","volume":"33","author":"Grabenbauer","year":"1999","journal-title":"Front Radiat Ther Oncol"},{"key":"10.1016\/j.ijrobp.2009.05.008_bib17","first-page":"152","article-title":"CPT-11: The European clinical development","volume":"6","author":"Terret","year":"1996","journal-title":"J Infus Chemother"},{"key":"10.1016\/j.ijrobp.2009.05.008_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002093.pub2","article-title":"Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer","volume":"3","author":"Yip","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijrobp.2009.05.008_bib19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1200\/JCO.1985.3.3.373","article-title":"Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil\u2014An Eastern Cooperative Oncology Group study","volume":"3","author":"Klaassen","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2009.05.008_bib20","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2005.06.023","article-title":"Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial","volume":"23","author":"Louvet","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2009.05.008_bib21","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/jnci\/80.10.751","article-title":"Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone","volume":"80","year":"1988","journal-title":"J Natl Cancer Inst"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301609007305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301609007305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T14:00:22Z","timestamp":1544709622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301609007305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0360301609007305"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2009.05.008","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}